Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359089 | 0.71 | PIK3CA (0.43) | ROCK2HPGDL3MBTL1 | |
| SCHEMBL6360442 | 0.60 | CASP1 (0.43) | L3MBTL1 | |
| SCHEMBL13963092 | 0.57 | RAB9A (0.61) | ROCK2HPGDL3MBTL1 | |
| SCHEMBL8524757 | 0.55 | MEN1 (0.44) | HPGDL3MBTL1 | |
| SCHEMBL2411151 | 0.55 | TAAR1 (0.58) | L3MBTL1 | |
| SCHEMBL8253294 | 0.54 | NPSR1 (0.43) | ROCK2HPGD | |
| SCHEMBL6784490 | 0.54 | TAAR1 (0.59) | — | |
| SCHEMBL8084560 | 0.54 | TAAR1 (0.59) | — | |
| SCHEMBL2309841 | 0.54 | RAB9A (0.48) | HPGDL3MBTL1 | |
| SCHEMBL18162511 | 0.53 | LMNA (0.53) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936607-B2 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNOBECK A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | ROCK2 4104/4885HPGD 2516/4885L3MBTL1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.